Highlights Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 16:35:16 15/07/2025 BST			5-day change	1st Jan Change
7.302 ^EUR	+2.79%		+1.42%	-10.90%

07-09	EVOTEC : Deutsche Bank reiterates its Neutral rating	ZD
06-26	EVOTEC : Warburg Research remains its Buy rating	ZD

Highlights

Evotec SE Joins the NURTuRE-AKI Consortium for Establishing Patient Cohort for Establishing A Patient Cohort for Establishing a Patient Cohort for Acute Kidney Injury	06-25	CI
Evotec recovers to March level	05-23	DP
Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins and Advance Small-Molecule Therapeutics at Scale	05-08	CI
Evotec Secures New Grant to Develop Tuberculosis Treatments	05-07	MT
Evotec SE Reports Earnings Results for the First Quarter Ended March 31, 2025	05-06	CI
Evotec starts the year with a decline in sales – shares lose significant ground	05-06	DP
Evotec Outlook FY Revenue EUR 840-880 Million	05-06	RE
Evotec Announces Progress In Protein Degradation Collaboration With Bristol Myers Squibb	04-24	RE
Evotec stands to gain $75 million from research alliance with Bristol-Myers Squibb	04-24	DP
Evotec SE Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb	04-24	CI
Warburg Research lowers target for Evotec to €12.10 – 'Buy'	04-23	DP
Medincell and iM4TB Initiate Development of A Long-Acting Injectable Version of Macozinone	04-22	CI
Evotec realigns itself – aims to accelerate growth	04-17	DP
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday	04-17	MT
Biotech Firm Evotec Meets Lowered Annual Targets	04-17	RE
Evotec SE Reports Earnings Results for the Full Year Ended December 31, 2024	04-17	CI
Evotec SE Provides Earnings Guidance for the Full Year of 2025 and Outlook for the Year 2028	04-17	CI
Evotec in demand – stabilization at a low level in the long term	04-17	DP
Evotec Provides 2025 Revenue Guidance	04-17	MT
Investors reward Evotec's longer-term outlook	04-17	DP
Evotec Outlook FY Revenue Eur 840-880 Mln	04-17	RE
RBC Says US Tariffs Could Hit European Life Science Tools Companies	04-03	MT
Evotec Gets $20 Million Payment from Bristol Myers Squibb Partnership	03-04	MT
Evotec Announces Key Progress In Neuroscience Collaboration With Bristol Myers Squibb	03-04	RE
Evotec Announces CFO Change	02-26	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Highlights

Filters